MikhailIShtivelbandMD

Oncology • Chandler, AZ

Join to view full profile

Dr. Shtivelband is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shtivelband's full profile

Already have an account?

Office
695 S Dobson Rd
Chandler, AZ 85224
Phone+1 480-821-2838

Fax+1 480-821-9444
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2000 - 2003
Quinnipiac University Frank H. Netter MD School of Medicine/St VIncent's Medical CenterResidency, Internal Medicine, 1997 - 2000
Chelyabinsk State Medical AcademyClass of 1991

Certifications & Licensure

AZ State Medical License 2004 - 2024
TX State Medical License 2003 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012

Clinical Trials

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2014 Feb 28
Completed
Phase 1
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Start of enrollment: 2016 Nov 30
Completed
Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
Terminated
Phase 3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

25 citations
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder...> ;The Lancet. Haematology. 2021 Apr 1
1 citations
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Roger M. Lyons, Mikhail Shtivelband, Edwin C. Kingsley, Mehdi Moezi, Donald A. Richards, Jeff P. Sharman, Xiaoshu Feng, Megan Cannan, Rafik Fellague-Chebra, Thomas E. ...> ;Leukemia & Lymphoma. 2021 Jan 15
36 citations
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, T. Wehler, Francisco Orlandi, Naoyuki Nogami, Carlo Barone, Denis Moro-Sibilot, Mikhail Shtivelband, José Luis González Larriba, Jeffrey Rothenstein, Mart...> ;Journal of Clinical Oncology. 2020 May 27
10 citations
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Ward, Bhuvaneswar...> ;Clinical Breast Cancer. 2019 Feb 28
16 citations
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer
David E. Gerber, David R. Spigel, David Giorgadze, Mikhail Shtivelband, Olga V. Ponomarova, Joseph Shan, Kerstin B. Menander, Chandra P. Belani> ;Clinical Lung Cancer. 2016 May 1
109 citations
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial
Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok, Kenneth J. O'Byrne, Michael Boyer, Joachim von Pawel, Adam Pluzanski, Mikhail Shtivelband, Lara Carmen Iglesias Docampo,...> ;The Lancet. Oncology. 2014 Nov 1
15 citations
Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.
Mikhail Shtivelband> ;Breast. 2013 Aug 1
2 citations
Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.
Pavani Chalasani, Mikhail I Shtivelband, Lee D. Cranmer> ;Clinical Advances in Hematology & Oncology. 2009 Jul 1
24 citations
Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer- binding protein β activation and cyclooxygenase-2 expression by salicylate
Katarzyna A. Cieslik, Ying Zhu, Mikhail Shtivelband, Kenneth K. Wu> ;The Journal of Biological Chemistry. 2005 May 6
48 citations
Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells but Does Not Affect Tumorigenicity in Vivo
Eric C. McGary, Amir Onn, Lisa Mills, Amy B. Heimberger, Omar Eton, Gary W. Thomas, Mikhail Shtivelband, Menashe Bar-Eli> ;The Journal of Investigative Dermatology. 2004 Feb 1
52 citations
A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo
Eric C. McGary, Amy B. Heimberger, Lisa Mills, Kristy L. Weber, Gary W. Thomas, Mikhail I. Shtivelband, Dina Lev, Menashe Bar-Eli> ;Clinical Cancer Research. 2003 Dec 15
21 citations
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts
Wu Guo Deng, Michael A. Saunders, Derek W. Gilroy, Xue Zhong He, Howard Yeh, Ying Zhu, Mikhail I. Shtivelband, Ke-He Ruan, Kenneth K. Wu> ;FASEB Journal. 2002 Aug 1
34 citations
Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression.
M. I. Shtivelband, Harinder S. Juneja, S. Lee, Kenneth K. Wu> ;Journal of Thrombosis and Haemostasis. 2003 Oct 1
Join now to see all

Journal Articles

Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...
H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology